Encouraging results from trial of inhaled drug – University of Southampton
The University of Southampton and drug-development-company Synairgen plc have announced positive results from clinical trials of a drug (SNG001 – inhaled formulation of interferon beta) that may prevent worsening of COVID-19 in those most at risk. The odds of developing severe disease (e.g. requiring ventilation or resulting in death) during the treatment period (day 1 […]